Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury
- Emilie Cornille†1,
- Mhamad Abou-Hamdan†1,
- Michel Khrestchatisky1,
- André Nieoullon2,
- Max de Reggi1 and
- Bouchra Gharib1Email author
© Cornille et al; licensee BioMed Central Ltd. 2010
Received: 22 October 2009
Accepted: 23 April 2010
Published: 23 April 2010
The administration of the ketone bodies hydroxybutyrate and acetoacetate is known to exert a protective effect against metabolic disorders associated with cerebral pathologies. This suggests that the enhancement of their endogenous production might be a rational therapeutic approach. Ketone bodies are generated by fatty acid beta-oxidation, a process involving a mitochondrial oxido-reductase superfamily, with fatty acid-CoA thioesters as substrates. In this report, emphasis is on the penultimate step of the process, i.e. L-3-hydroxybutyryl-CoA dehydrogenase activity. We determined changes in enzyme activity and in circulating ketone body levels in the MPTP mouse model of Parkinson's disease. Since the active moiety of CoA is pantetheine, mice were treated with pantethine, its naturally-occurring form. Pantethine has the advantage of being known as an anti-inflammatory and hypolipidemic agent with very few side effects.
We found that dehydrogenase activity and circulating ketone body levels were drastically reduced by the neurotoxin MPTP, whereas treatment with pantethine overcame these adverse effects. Pantethine prevented dopaminergic neuron loss and motility disorders. In vivo and in vitro experiments showed that the protection was associated with enhancement of glutathione (GSH) production as well as restoration of respiratory chain complex I activity and mitochondrial ATP levels. Remarkably, pantethine treatment boosted the circulating ketone body levels in MPTP-intoxicated mice, but not in normal animals.
These finding demonstrate the feasibility of the enhancement of endogenous ketone body production and provide a promising therapeutic approach to Parkinson's disease as well as, conceivably, to other neurodegenerative disorders.
A frequent feature of neurodegenerative diseases is the impairment of glucose metabolism, the primary post-embryonal cerebral energy source (review in ). However, the brain also has the ability to adapt its metabolism and increase its reliance on lipids for energy production, through the fatty acid β-oxidation pathway. The process involves L-3-hydroxyacyl-CoA dehydrogenase (HAD) (EC 184.108.40.206) activity which generates ketone bodies (KBs) [2, 3]. The end product, acetyl-CoA, feeds into the TCA cycle to produce energy in the form of NADH and FADH2. The KBs β-hydroxybutyrate (β-OHB) and acetoacetate (ACA) have a protective role in a broad spectrum of cerebral injuries and diseases and they preserve neuronal cell integrity and stability in vitro [4–6]. The experimental approaches used are intravenous infusion of mice or rats with β-OHB [1, 7] or administration of a ketogenic diet. The utilization of β-OHB by the brain and other tissues is contingent on its dehydrogenation to ACA. Little is known, however, about what events in diseased animals, regarding changes in β-oxidation rate and KB levels associated with cerebral disorders.
We therefore investigated changes in fatty acid β-oxidation in the MPTP mouse model of Parkinson's disease (PD). The disorders result from a multifactorial cascade of deleterious factors  leading to a progressive degeneration of dopaminergic neurons of the substantia nigra and resulting in motor troubles. A hallmark of the pathological process is the decrease of mitochondrial function, in particular the inhibition of electron transport system complex I [9–12] associated with oxidative stress. Depletion of GSH levels, observed in the substantia nigra of PD patients, as well as in the MPTP model, is one of the earliest events leading to the inhibition of complex I and subsequent mitochondrial dysfunction [13, 14].
Experimental data published already in the 1980's indicated that pantethine, a low-molecular-weight thiol widely distributed in the living world, circumvents the impairment of fatty acid β-oxidation in rat liver mitochondria and microvessels of the brain [15, 16]. Pantethine is also well known to stimulate lipolysis and, conversely, to inhibit fatty acid synthesis . MPTP-intoxicated mice display impaired energy production , that is improved by KB infusion . We therefore investigated the effects of pantethine treatment in this model. We determined the changes in the NAD-dependent conversion of 3-hydroxybutyryl-CoA to acetoacetyl-CoA. Our main finding is that i) the dehydrogenase activity and circulating KB levels decreased in intoxicated mice and ii) these parameters were restored by pantethine treatment, with improvement of dopaminergic injury and functional disorders.
Unless otherwise mentioned, all chemicals and reagents were obtained from Sigma-Aldrich Chemical Company (St. Louis, MO) as the highest available grades.
Animals and treatment
Ten-week old male C57BL/6 mice were purchased from Janvier (Le Genest, France). They were handled according to the rules of "Décret #87-848 du 19/10/1987, Paris"; approval #007031. Mice were administered 1-methyl-4-(2'-methylphenyl)-1,2,3,6- tetrahydropyridine (abbreviated as 2'-methyl-MPTP), a more potent neurotoxin in mice than MPTP [20, 21]. The neurotoxin was given via i.p. injections, at 20 mg/kg, according to a method described previously . Unless otherwise mentioned, two 2'-methyl-MPTP injections were performed on the same day at a 6 h interval, followed by one injection on the following day. This protocol caused an about 80% loss of striatal dopamine levels. D-pantethine was indicated by the manufacturer to be 97% pure. Purity of the preparation was further ascertained using HPLC-mass spectrometry analysis (LCUV-MSD analysis) (SCA CNRS, Lyon, France). Mice received two 5-day treatments with daily i.p. injections of 15 mg of pantethine, before and after 2'-methyl-MPTP administration. Preliminary experiments showed that this regimen was well tolerated and gave the best results for an as short as possible treatment. Intraperitoneal administration avoids extensive hydrolysis of pantethine by intestinal pantetheinase. The high dosage used is made necessary by the quick elimination of pantethine into the urine . When used, pantothenate was injected at a molar concentration equivalent to that of pantethine; for cystamine, the highest non-toxic dose was used, i.e. 1.875 mg per mouse. The solutions were prepared in apyrogenic 0.9% NaCl solution. Control animals were injected with the same saline solution.
Pantethine reduction to pantetheine was performed using the disulfide reducing gel TCEP (Tris (2-carboxyethyl) phosphine) according to the manufacturer's instructions (Pierce Chemical, Rockford, IL). Briefly, the gel was washed with 50 mM pH 7.5 phosphate buffer and then incubated with pantethine solution for 1 h at room temperature. Pantethine reduction was checked by scanning the UV-absorption spectrum using a Beckman DU800 spectrophotometer. The decrease of the 245 nm-peak until complete extinction indicated complete reduction.
Isolation of mitochondria
Brain and liver tissue were homogenized in mitochondria extraction buffer (IMGENEX, Cliniscience, Montrouge, France) according to the manufacturer's instructions. Brain mitochondria were isolated using a discontinuous Percoll gradient . After a 10 min centrifugation at 30 400 × g, the mitochondrial layer was collected and washed 3 times with 10 ml of extraction buffer. Liver mitochondria were prepared as described previously . Mitochondrial pellets were then resuspended in a hypotonic buffer composed of (25 mM KH2PO4 and 5 mM MgCl2, pH 7.5). Protein concentration was determined by the Biorad assay method. Isolated mitochondria were checked for membrane integrity by assaying citrate synthase activity.
Determination of L-3-hydroxybutyryl-CoA dehydrogenase activity and of circulating KB levels
We performed time course studies to assess 2'-methyl-MPTP-induced changes in fatty acid β-oxdation. L-3-hydroxybutyryl-CoA dehydrogenase activity was assayed both in the brain and liver, since the neurotoxin-induced injuries are not limited to the brain [26, 27]. Control and pantethine-treated mice (15 mg/5 days) received two 2'-methyl-MPTP injections on the same day at 6 h intervals. Under these conditions, the neurotoxin induces an active neurological phase ranging from 12 hours to 4 days after the last injection, followed by a progressive recovery . Brain and liver mitochondrial samples were prepared 1, 2, 4 and 7 days following MPTP injections. Dehydrogenase activity was determined in the forward direction, as it occurs in vivo . We used 125 μM β-hydroxybutyryl-CoA as a substrate  in an assay medium containing 75 mM Tris (pH 10) with 75 mM KCl, NAD+ 1.2 mM. Reduction of NAD was followed at 340 nm, with an extinction coefficient taken as 6.22 mM-1cm-1. Control assays were conducted in the absence of the substrate. For determination of hydroxybutyrate and acetoacetate levels, blood samples were taken from the retro-orbital plexus of halothane-anesthetized mice into capillary tubes containing 3.8% sodium citrate. Blood was immediately deproteinized with 4% perchloric acid, centrifuged at 17 500 × g, 15 min at 4°C. Ketone bodies were quantified using enzymatic assay kits (Biosentec, Toulouse, France) based on the reduction of NAD or oxidation of NADH, followed at 340 nm in a spectrophotometer. The assays were repeated three times.
Mass spectrometry analysis
Changes in brain GSH levels following pantethine injection were determined using HPLC-mass spectrometry analysis (LCUV-MSD analysis) (SCA CNRS, Lyon, France). Healthy mice received a single i.p. injection of 15 mg of pantethine and were then sacrificed at different times, from 30 min to 4 h. Blood samples were taken from the retro-orbital plexus of halothane-anesthetized mice into capillary tubes containing 3.8% trisodium citrate. Mice were then perfused with heparinized saline. Perfused brain and plasma samples were immediately homogenized in 3 volumes of 4% perchloric acid. Samples were centrifuged at 20,000 × g for 10 min at 4°C; the supernatants were snap-frozen in liquid nitrogen and stored at -80°C pending assay. Samples were analyzed using the HP1100-MSD (B) system with HPChemstation software, version A.08.01-682. Chromatographic separations were performed by reverse-phase chromatography on a 2 mm (inner diameter) C18 Waters Hilic column. A gradient of 0.05% formic acid pH 2.6/acetonitrile was delivered over 15 min to elute the compounds at a flow rate of 300 μl/min. Compounds were ionized by electrospray (ES+) ionization. The mass spectral data were processed into peak lists containing the characteristic [M+H]+ ion m/z = 308.
Brain glutathione assays
Saline or pantethine-treated mice were anesthetized with halothane on days 1 and 7 following the last neurotoxin injection. Brain samples were frozen immediately in liquid nitrogen and homogenized in 9 volumes of 100 mM potassium phosphate buffer pH 7.5 containing 1 mM EDTA. An aliquot of the homogenate was added to an equal volume of 5-sulfosalicylic acid (1% w/v). After centrifugation at 8,000 g for 10 min, the total glutathione (GSH + GSSG) concentration in the supernatant was determined with the colorimetric GSH assay Kit (ApoGSH Glutathione Colorimetric Assay Kit, MBL, Woburn, MA) according to the manufacturer's instruction.
Complex I activity
For in vivo treatment, brain mitochondria were isolated from mice treated with 15 mg of pantethine for 5 days. For in vitro treatment, pantethine or pantetheine were added to mitochondria isolated from control mice. Complex I activity was determined based on protocols described previously . Mitochondria were lysed by freeze-thawing three times. To initiate the reaction, 150 μg-protein extracts were added to the hypotonic assay buffer containing (65 μM ubiquinone1, 130 μM NADH, 2 μg/ml of antimycin A, and 2.5 mg/ml of defatted BSA), in the presence of different concentrations of MPP+ (0, 1.25, 2.5 mM). Pantetheine or pantethine (0, 0.5 or 1 mM) was added 5 min later. The oxidation of NADH was monitored spectrophotometrically at 340 nm for 3 min at 30°C prior to the addition of the complex I inhibitor rotenone (2 μg/ml), after which the activity was measured for an additional 3 min. The differential rate before and after the addition of rotenone was used to calculate complex I activity. We checked, using the Ellman's reagent, that the reduced form pantetheine was maintained throughout the experiment.
Brain mitochondria were suspended in respiration buffer consisting of (225 mM mannitol, 75 mM sucrose, 10 mM KCl, 5 mM HEPES, 5 mM K2HPO4 pH 7.5), with freshly added 1 mg/ml of defatted BSA at 30°C. Oxygen consumption was measured in a closed-chamber cuvette with a mini-stirring bar using a Clark-type electrode (VWR Fontenay sous Bois, France). To assess complex I-mediated mitochondrial respiration, a one mg-protein preparation in 1 ml of respiration buffer was preincubated with 10 mM glutamate and 5 mM malate in the presence of MPP+ (0, 50 and 100 μM) at 30°C. After 5 min of incubation, pantetheine at (0, 0.5 or 1 mM) was added and the oxygen consumption was measured for an additional time before the addition of 500 uM ADP to induce state 3 respiration. Oxygen consumption was monitored throughout the experiment.
Samples were prepared under conditions identical to those of the polarographical study. Mitochondria suspended in respiration buffer were incubated in the presence of MPP+ (0, 50 or 100 μM). Pantetheine (0, 0.5 or 1 mM) was added 5 minutes later. After the reaction was stopped, the mitochondrial suspension was lysed in an equal volume of lysis buffer from the ATP bioluminescence assay kit (Sigma), and the content of ATP was measured according to the manufacturer's instructions. Light emitted from luciferase-mediated reaction was captured in a Beckman DTX800 luminometer and calculated from a log-log plot of a standard curve of known ATP concentrations.
Striatal dopamine levels and motor activity
Saline and pantethine-treated mice were sacrificed by decapitation on day 7 after the last 2'-methyl-MPTP administration and the striata were collected and stored at -80°C until analysis. The endogenous levels of dopamine (DA) and its metabolites, dihydroxyphenyl acetic acid (DOPAC) and homovanillic acid (HVA), were determined using high performance reverse phase liquid chromatography with electrochemical detection according to the method described previously . Before being sacrificed, the mice were used for the determination of hypokinesia-like symptoms, using the iron pole test according to the method described previously [33, 34]. After pre-trial acclimatization, each mouse was given six consecutive trials and the mean of the three best trials was retained. Animals which died before the test were noted as having required 60 sec.
Tyrosine hydroxylase (TH) immunohistochemistry and quantitative analysis
Mice received two 2'-methyl-MPTP injections on the same day at 6 h interval, followed by one injection on the following day. They were treated with saline or pantethine for 5 days, before and after the neurotoxin injections, and they were then sacrificed by decapitation. Brain coronal sections (10 μm), cut every 100 μm, were incubated with a rabbit anti-TH antibody (Calbiochem-Novabiochem, San Diego, CA) (1:1000) followed by peroxidase-conjugated anti-IgG antibody (Jackson ImmunoResearch, obtained from Beckman Coulter, Marseille, France). Immunoreactivity was visualized by incubation in 0.1% 3,3'-diaminobenzidine tetrahydrochloride (DAB) and quantified using LUCIA image analysis software (Laboratory Imaging, Prague, Czech Republic). For the determination of dopaminergic cell loss, the sections were counterstained with cresyl violet (Sigma-Aldrich). The number of TH-positive neurons in the substantia nigra pars compacta (SNpc) was estimated using a semi-quantitative method . The area of the SNpc was determined at low magnification (4× objective) and neurons were counted at higher magnification (40× objective) in three microscopic fields (area of 40,000 μm2 each) situated on the mediolateral axis of the SN of each histological section. Neuronal density was calculated as the ratio between the sum of neuronal counts and the sum of the areas of 5 sections and is expressed as number of neurons per square millimeter.
Nonparametric Mann-Whitney U tests were performed using GraphPad Prism software. Dopamine levels and motor activity time data were analyzed using the Newman-Keuls test for groups; p < 0.05 was considered significant.
L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating KB levels
Effects of pantethine treatment on L-3-hydroxybutyryl-CoA dehydrogenase activity.
Days after 2'methyl
L-3-hydroxybutyryl-CoA dehydrogenase activity
63.91 ± 4.90
73.95 ± 2.55#
2.96 ± 0.35
3.11 ± 0.27
28.91 ± 3.54**
51.09 ± 4.87##
2.74 ± 0.14
3.56 ± 0.18#
35.58 ± 3.31**
45.82 ± 3.84#
2.08 ± 0.17**
2.94 ± 0.19##
45.01 ± 5.19*
46.01 ± 5.05
1.60 ± 0.27**
2.98 ± 0.32##
54.31 ± 4.95
57.55 ± 3.65
2.67 ± 0.18
2.85 ± 0.17
Preservation of GSH stores by pantethine treatment.
Days following 2'-methyl-MPTP injection
2.00 ± 0.13
1.81 ± 0.09
2'-methyl-MPTP + saline
1.25 ± 0.18
1.66 ± 0.20
2'-methyl-MPTP + pantethine
1.96 ± 0.12§
1.79 ± 0.10
Control + pantethine
2.54 ± 0.29#
Dopaminergic structures and motor ability
We showed that the neurotoxin 2'-methyl-MPTP inhibited L-3-hydroxybutyryl-CoA dehydrogenase activity and caused a concomitant fall of circulating levels of the product of the reaction, acetoacetate (ACA). These alterations were avoided by pantethine treatment. The protective effect of pantethine was associated with the enhancement of GSH synthesis, restoration of mitochondrial function, i.e. complex I activity, ATP synthesis and oxygen consumption, leading to a protection against dopaminergic injury.
KBs are produced by hepatocytes and are transported to the tissues, including the brain; astrocytes are also ketogenic, although to a lesser extent however . In agreement, we found that dehydrogenase activity is two-orders of magnitude higher in the liver than in the brain, and circulating KB levels correlate with enzyme activity of the liver. We observed that injection of the neurotoxin induced, in both brain and liver, a decrease of dehydrogenase activity, which was restored by pantethine treatment. These findings may be compared with published data on L-3-hydroxyacyl-CoA dehydrogenase type II/amyloid binding alcohol dehydrogenase (HADHII/ABAD). The enzyme is downregulated in PD patients and in the mouse, on days 2 to 7 after MPTP injection. Conversely, transgenic mice with increased expression of human HADHII/ABAD are significantly more resistant to MPTP; overexpression of the enzyme mitigates MPTP-induced impairment of oxidative phosphorylation and ATP production . Thus the changes of dehydrogenase activity that we observed following MPTP injection and pantethine treatment may reflect changes in the amount of the enzyme.
Pantethine is metabolized in vivo, yielding mainly pantetheine, cysteamine, pantothenic acid and 4'-phosphopantetheine (4'-PP) . All these derivatives may well be involved in the effects that we observed after treatment with pantethine. The treatment increased the GSH concentration, which is likely to be mediated by the increase of intracellular levels of L-cysteine via disulfide exchange reactions. Free cysteine is available to several pathways, including formation of mixed disulfides, and synthesis of glutathione . The maintenance of normal GSH levels is essential for NADH-ubiquinone oxido-reductase (complex I) activity since the complex I is thiol-regulated [13, 40, 41]. Accordingly, we found that, when applied to isolated mitochondria, the reduced form pantetheine was able to preserve complex I activity, and therefore to maintain complex I redox status; the oxidized form pantethine did not. It should be underlined that GSH and CoA levels, as well as complex I activity and ATP production are interdependent and their interactions remain to be clarified [42, 43].
Our main finding is that the administration of pantethine to 2'-methyl-MPTP intoxicated mice stimulates fatty acid β-oxidation and increases circulating KB levels.
This effect is specific for pantethine and was not observed with cystamine. This may reflect the fact that pantetheine constitutes the active moiety of CoA. Not only CoA-fatty acid thioesters but also pantetheine- and 4'PP-fatty acid thioesters are acceptable substrates for HAD. In comparison, cysteamine is a too small an entity; the HAD K m value is 125 fold higher for acyl-cysteamine than for acyl-pantetheine . The thiol group and the pantoic acid moiety (2,4-dihydroxy-3-dimethyl butyric acid) of pantetheine play a central role in enzyme binding [44, 45]. These elements do not occur in either pantothenic acid or cysteamine, respectively. Accordingly, under our experimental conditions, these two compounds were unable to enhance either dehydrogenase activity or circulating levels of KB (data not shown). Pantethine also displays anti-inflammatory activity in inhibiting the activation of the cellular response to pro-inflammatory factors, as we reported earlier .
In summary, treatment with pantethine reproduces the effects of KB administration and ketogenic diets with however several advantages. First, the stimulation of KB synthesis is a rational way to enhance KB levels. Second, long-term administration of high fat diets has detrimental effects  that could be circumvent by the hypolididemic properties of pantethine. Third, pantethine has apparently no effects on circulating ACA levels under normal conditions, meaning that it could act "on demand" only.
It is now becoming clear that the cerebral hypometabolism in major diseases such as PD and Alzheimer's disease [48, 49] constitutes a therapeutic target. Treatments able to enhance neuronal energy reserves may improve the ability of neurons to resist metabolic challenges  and may be effective in relieving physiological as well as cognitive dysfunctions. Pantethine seems to promote metabolic flexibility, i.e. the transition between carbohydrate and lipid utilization for energy production and is therefore a good candidate drug against diseases associated with metabolic disorders. Under our experimental conditions, we used high doses of pantethine; however, in view of a potential clinical application, an appropriate delivery device may improve the efficiency of treatment and allow a drastic reduction of the dose to be administered.
The work was supported by funding from the CNRS, the Université de la Méditerranée and Cerebel SA (Switzerland). HPLC-mass spectrometry analyses were performed by Olivier Paissé, CNRS SCA, Lyon, France. The authors thank Howard Rickenberg for useful comments and criticisms.
- Prins ML: Cerebral metabolic adaptation and ketone metabolism after brain injury. J Cereb Blood Flow Metab. 2008, 28: 1-16. 10.1038/sj.jcbfm.9600543.PubMed CentralView ArticlePubMed
- Yang SY, He XY, Schulz H: 3-Hydroxyacyl-CoA dehydrogenase and short chain 3-hydroxyacyl-CoA dehydrogenase in human health and disease. Febs J. 2005, 272: 4874-4883. 10.1111/j.1742-4658.2005.04911.x.View ArticlePubMed
- Filling C, Keller B, Hirschberg D, Marschall HU, Jornvall H, Bennett MJ, Oppermann U: Role of short-chain hydroxyacyl CoA dehydrogenases in SCHAD deficiency. Biochem Biophys Res Commun. 2008, 368: 6-11. 10.1016/j.bbrc.2007.10.188.View ArticlePubMed
- Izumi Y, Ishii K, Katsuki H, Benz AM, Zorumski CF: beta-Hydroxybutyrate fuels synaptic function during development. Histological and physiological evidence in rat hippocampal slices. J Clin Invest. 1998, 101: 1121-1132. 10.1172/JCI1009.PubMed CentralView ArticlePubMed
- Imamura K, Takeshima T, Kashiwaya Y, Nakaso K, Nakashima K: D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease. J Neurosci Res. 2006, 84: 1376-1384. 10.1002/jnr.21021.View ArticlePubMed
- Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL: D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA. 2000, 97: 5440-5444. 10.1073/pnas.97.10.5440.PubMed CentralView ArticlePubMed
- Maalouf M, Rho JM, Mattson MP: The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev. 2009, 59: 293-315. 10.1016/j.brainresrev.2008.09.002.PubMed CentralView ArticlePubMed
- Przedborski S: Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord. 2005, 11 (Suppl 1): S3-7. 10.1016/j.parkreldis.2004.10.012.View ArticlePubMed
- Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, Carelli V, Martinuzzi A, Hirano M, Przedborski S, Vila M: Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA. 2005, 102: 19126-19131. 10.1073/pnas.0508215102.PubMed CentralView ArticlePubMed
- Greenamyre JT, Sherer TB, Betarbet R, Panov AV: Complex I and Parkinson's disease. IUBMB Life. 2001, 52: 135-141. 10.1080/15216540152845939.View ArticlePubMed
- Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD: Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990, 54: 823-827. 10.1111/j.1471-4159.1990.tb02325.x.View ArticlePubMed
- Vyas I, Heikkila RE, Nicklas WJ: Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem. 1986, 46: 1501-1507. 10.1111/j.1471-4159.1986.tb01768.x.View ArticlePubMed
- Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu RM, Forman HJ, Andersen JK: Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J Biol Chem. 2000, 275: 26096-26101. 10.1074/jbc.M000120200.View ArticlePubMed
- Chinta SJ, Andersen JK: Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic Biol Med. 2006, 41: 1442-1448. 10.1016/j.freeradbiomed.2006.08.002.View ArticlePubMed
- Miyazawa S, Furuta S, Hashimoto T: Reduction of beta-oxidation capacity of rat liver mitochondria by feeding orotic acid. Biochim Biophys Acta. 1982, 711: 494-502.View ArticlePubMed
- Morisaki N, Matsuoka N, Shirai K, Sasaki N, Saito Y, Kumagai A: Effect of pantethine on fatty acid oxidation in microvessels of rat brain. Tohoku J Exp Med. 1983, 141: 41-45. 10.1620/tjem.141.41.View ArticlePubMed
- Bocos C, Herrera E: Pantethine stimulates lipolysis in adipose tissue and inhibits cholesterol and fatty acid synthesis in liver and intestinal mucosa in the normolipidemic rat. Environmental Toxicology and Pharmacology. 1998, Elsevier Science B.V, 6 (1): 59-66. 10.1016/S1382-6689(98)00020-9.
- Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF: Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999, 157: 142-149. 10.1006/exnr.1999.7049.View ArticlePubMed
- Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, Yan SD, Naini A, Vila M, Jackson-Lewis V, Ramasamy R, et al.: D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest. 2003, 112: 892-901.PubMed CentralView ArticlePubMed
- Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE: MPTP, MPP+ and mitochondrial function. Life Sci. 1987, 40: 721-729. 10.1016/0024-3205(87)90299-2.View ArticlePubMed
- Sonsalla PK, Youngster SK, Kindt MV, Heikkila RE: Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J Pharmacol Exp Ther. 1987, 242: 850-857.PubMed
- Abdel-Wahab MH: Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity-induced by 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) in mice. J Biochem Mol Toxicol. 2005, 19: 32-41. 10.1002/jbt.20053.View ArticlePubMed
- Yoshimura H, Shiraki H, Oguri K, Tsukamoto H: [Metabolism of drugs. LXVI. Studies on the metabolic fate of pantethine]. Yakugaku Zasshi. 1970, 90: 364-369.PubMed
- Brown MR, Sullivan PG, Geddes JW: Synaptic mitochondria are more susceptible to Ca2+overload than nonsynaptic mitochondria. J Biol Chem. 2006, 281: 11658-11668. 10.1074/jbc.M510303200.View ArticlePubMed
- Ferraro P, Nicolosi L, Bernardi P, Reichard P, Bianchi V: Mitochondrial deoxynucleotide pool sizes in mouse liver and evidence for a transport mechanism for thymidine monophosphate. Proc Natl Acad Sci USA. 2006, 103: 18586-18591. 10.1073/pnas.0609020103.PubMed CentralView ArticlePubMed
- Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW: Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol. 1995, 37: 714-722. 10.1002/ana.410370604.View ArticlePubMed
- Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP, Davis RE, Parker WD: Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol. 1996, 40: 663-671. 10.1002/ana.410400417.View ArticlePubMed
- Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S: Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 1995, 4: 257-269. 10.1016/1055-8330(95)90015-2.View ArticlePubMed
- Birktoft JJ, Holden HM, Hamlin R, Xuong NH, Banaszak LJ: Structure of L-3-hydroxyacyl-coenzyme A dehydrogenase: preliminary chain tracing at 2.8-A resolution. Proc Natl Acad Sci USA. 1987, 84: 8262-8266. 10.1073/pnas.84.23.8262.PubMed CentralView ArticlePubMed
- Yan SD, Zhu Y, Stern ED, Hwang YC, Hori O, Ogawa S, Frosch MP, Connolly ES, McTaggert R, Pinsky DJ, et al.: Amyloid beta -peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress. J Biol Chem. 2000, 275: 27100-27109.PubMed
- Birch-Machin MA, Turnbull DM: Assaying mitochondrial respiratory complex activity in mitochondria isolated from human cells and tissues. Methods Cell Biol. 2001, 65: 97-117. full_text.View ArticlePubMed
- Amalric M, Moukhles H, Nieoullon A, Daszuta A: Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci. 1995, 7: 972-980. 10.1111/j.1460-9568.1995.tb01085.x.View ArticlePubMed
- Matsuura K, Kabuto H, Makino H, Ogawa N: Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods. 1997, 73: 45-48. 10.1016/S0165-0270(96)02211-X.View ArticlePubMed
- Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y: A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol. 1985, 50: 435-441.PubMed
- Battaglia G, Busceti CL, Molinaro G, Biagioni F, Traficante A, Nicoletti F, Bruno V: Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci. 2006, 26: 7222-7229. 10.1523/JNEUROSCI.1595-06.2006.View ArticlePubMed
- Guzman M, Blazquez C: Is there an astrocyte-neuron ketone body shuttle?. Trends Endocrinol Metab. 2001, 12: 169-173. 10.1016/S1043-2760(00)00370-2.View ArticlePubMed
- Tieu K, Perier C, Vila M, Caspersen C, Zhang HP, Teismann P, Jackson-Lewis V, Stern DM, Yan SD, Przedborski S: L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease. Ann Neurol. 2004, 56: 51-60. 10.1002/ana.20133.View ArticlePubMed
- Dupre S, Graziani MT, Rosei MA, Fabi A, Del Grosso E: The enzymatic breakdown of pantethine to pantothenic acid and cystamine. Eur J Biochem. 1970, 16: 571-578. 10.1111/j.1432-1033.1970.tb01119.x.View ArticlePubMed
- Butler JD, Zatz M: Pantethine and cystamine deplete cystine from cystinotic fibroblasts via efflux of cysteamine-cysteine mixed disulfide. J Clin Invest. 1984, 74: 411-416. 10.1172/JCI111436.PubMed CentralView ArticlePubMed
- Sriram K, Shankar SK, Boyd MR, Ravindranath V: Thiol oxidation and loss of mitochondrial complex I precede excitatory amino acid-mediated neurodegeneration. J Neurosci. 1998, 18: 10287-10296.PubMed
- Annepu J, Ravindranath V: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced complex I inhibition is reversed by disulfide reductant, dithiothreitol in mouse brain. Neurosci Lett. 2000, 289: 209-212. 10.1016/S0304-3940(00)01300-8.View ArticlePubMed
- Moiseenok AG, Komar VI, Khomich TI, Kanunnikova NP, Slyshenkov VS: Pantothenic acid in maintaining thiol and immune homeostasis. Biofactors. 2000, 11: 53-55. 10.1002/biof.5520110115.View ArticlePubMed
- Slyshenkov V, Dymkowska D, Wojtczak L: Pantothenic acid and pantothenol increase biosynthesis of glutathione by boosting cell energetics. FEBS Lett. 2004, 269: 169-172. 10.1016/j.febslet.2004.05.044.View Article
- Hartmann D, Philipp R, Schmadel K, Birktoft JJ, Banaszak LJ, Trommer WE: Spatial arrangement of coenzyme and substrates bound to L-3-hydroxyacyl-CoA dehydrogenase as studied by spin-labeled analogues of NAD+ and CoA. Biochemistry. 1991, 30: 2782-2790. 10.1021/bi00225a007.View ArticlePubMed
- Bradshaw RA, Noyes BE: L-3-hydroxyacyl coenzyme A dehydrogenase from pig heart muscle. EC 220.127.116.11 L-3-hydroxyacyl-CoA: NAD oxidoreductase. Methods Enzymol. 1975, 35: 122-128. 10.1016/0076-6879(75)35147-1.View ArticlePubMed
- Penet MF, Abou-Hamdan M, Coltel N, Cornille E, Grau GE, de Reggi M, Gharib B: Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc Natl Acad Sci USA. 2008, 105: 1321-1326. 10.1073/pnas.0706867105.PubMed CentralView ArticlePubMed
- Zhao Q, Stafstrom CE, Fu DD, Hu Y, Holmes GL: Detrimental effects of the ketogenic diet on cognitive function in rats. Pediatr Res. 2004, 55: 498-506. 10.1203/01.PDR.0000112032.47575.D1.View ArticlePubMed
- Klein RC, de Jong BM, de Vries JJ, Leenders KL: Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson's disease. Mov Disord. 2005, 20: 1021-1030. 10.1002/mds.20493.View ArticlePubMed
- Costantini LC, Barr LJ, Vogel JL, Henderson ST: Hypometabolism as a therapeutic target in Alzheimer's disease. BMC Neurosci. 2008, 9 (Suppl 2): S16-10.1186/1471-2202-9-S2-S16.PubMed CentralView ArticlePubMed
- Gasior M, Rogawski MA, Hartman AL: Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol. 2006, 17: 431-439. 10.1097/00008877-200609000-00009.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.